Furthermore, baicalein has exhibited the ability to hinder angiogenesis via multiple pathways, reducing expression levels of HIF-α, VEGF, NF-κB, and c-Myc in ovarian cancer cells [49], decreases the hypoxia-induced genes expression of hypoxia-responsive COX-2, VEGF, and iNOS by hindering the PI3K/Akt and ROS signaling in BV2 microglia [50], and attenuates the phosphorylation of VEGF2 and ERK in baicalein-treated HUVECs by lowering G1-related proteins expression, leading to stalling the cell cycle at the G1/S boundary, and affecting the p53/Rb signaling [51]. This evidence concerns the gene MAPK1 and ovarian carcinoma.